The upcoming report from Bausch + Lomb (BLCO) is expected to reveal quarterly earnings of $0.24 per share, indicating no change from the year-ago quarter compared to the year-ago period. Analysts forecast revenues of $1.27 billion, representing an increase of 7.9% year over year.
The consensus EPS estimate for the quarter has been revised 5.8% lower over the last 30 days to the current level. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during this timeframe.
Before a company announces its earnings, it is essential to take into account any changes made to earnings estimates. This is a valuable factor in predicting the potential reactions of investors toward the stock. Empirical research has consistently shown a strong correlation between trends in earnings estimate revisions and the short-term price performance of a stock.
While investors typically use consensus earnings and revenue estimates as a yardstick to evaluate the company's quarterly performance, scrutinizing analysts' projections for some of the company's key metrics can offer a more comprehensive perspective.
Bearing this in mind, let's now explore the average estimates of specific Bausch + Lomb metrics that are commonly monitored and projected by Wall Street analysts.
The average prediction of analysts places 'Revenue- Vision Care' at $708.34 million. The estimate suggests a change of +7% year over year.
Based on the collective assessment of analysts, 'Revenue- Pharmaceuticals' should arrive at $335.50 million. The estimate suggests a change of +9.3% year over year.
According to the collective judgment of analysts, 'Revenue- Product sales' should come in at $1.26 billion. The estimate suggests a change of +7.7% year over year.
Analysts forecast 'Revenue- Surgical' to reach $215.26 million. The estimate indicates a change of +5.5% from the prior-year quarter.
Analysts predict that the 'Revenue- Other' will reach $5.00 million.
View all Key Company Metrics for Bausch + Lomb here>>>
Shares of Bausch + Lomb have demonstrated returns of -5.5% over the past month compared to the Zacks S&P 500 composite's +4.7% change. With a Zacks Rank #4 (Sell), BLCO is expected to lag the overall market performance in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Bausch + Lomb Corporation (BLCO) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.